SCHEMBL14257534

SCHEMBL14257534

N#C/N=C(\Nc1ccccc1Cl)Oc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.47
MEN1 O00255 8/20 0.47
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KDM4E B2RXH2 3/20 0.40
MAPT P10636 4/20 0.38
LMNA P02545 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HTT P42858 3/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3644300 1.00 KMT2A (0.47) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL14257600 0.90 ALDH1A1 (0.47) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL9932583 0.85 KMT2A (0.45) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL9932581 0.85 KMT2A (0.45) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL14257526 0.84 KMT2A (0.43) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL11244909 0.84 HPGD (0.41) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL11244903 0.84 HPGD (0.41) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL14257580 0.82 NPC1 (0.46) KMT2ANPC1RAB9ANPSR1HPGD
SCHEMBL14267810 0.82 KMT2A (0.39) KMT2AMEN1ALDH1A1CYP1A2POLB
SCHEMBL4777719 0.82 RAB9A (0.43) KMT2AMEN1NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076924-A1 Piperazines as P2X7 antagonists ABBOTT LABORATORIES 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076924-A1 Piperazines as P2X7 antagonists P2RX7, P2RX1, P2RX2 KMT2A 3643/4885MEN1 4288/4885NPC1 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.